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Inhibitors of tropomyosin-related kinases (TRKs) display remarkable outcomes in the
regression of cancers harboring the Neurotrophin Receptors Tyrosine Kinase (NTRK)
fusion gene. As a result, TRKs have become attractive targets in anti-cancer drug
discovery programs. Here, we demonstrate that AZD4547, a highly potent and
selective inhibitor of fibroblast growth factor receptor (FGFR), displays anti-tumor
activity against KM12(Luc) harboring the TPM3-NTRK1 fusion gene associated with its
direct inhibition of TRKs. The results of profiling, using a 64-member in-house cancer cell
panel, show that AZD4547 displays anti-proliferation activity against KM12(Luc) with a
GI50 of 100 nM. In vitro biochemical assays reveal that AZD4547 has IC50 values of 18.7,
22.6 and 2.9 nM against TRKA, B and C, respectively. In a cellular context, AZD4547
blocks auto-phosphorylation of TRKs and phosphorylation of its downstream molecules
including PLC-gamma and AKT in a dose dependent manner. Also, AZD4547 at 0.1 mM
concentration downregulates expression of MAPK target genes (DUSP6, CCND1 and
ETV1) as well as the E2F pathway. Furthermore, AZD4547 induces G0/G1 arrest and
apoptosis, and suppresses anchorage independent growth of KM12(Luc). Oral
administration of 40 mpk AZD4547 dramatically delays tumor growth in a KM12(Luc)
implemented xenograft model, without promoting body weight changes. The capability of
AZD4547 to inhibit TRKA, TRKB and clinically relevant mutants (TRKA G595R, G667S,
G667C and G667A) was also evaluated using Ba/F3 cells harboring the ETV6-NTRKs
fusion gene. The combined observations demonstrate the potential application of
AZD4547 for treatment of NTRK fusion driven cancers.
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Receptor tyrosine kinases are among the most frequently
dysregulated proteins involved in cancers (1). As a result, these
kinases have become key drug targets in studies conducted
during the past two decades. Thus far (2021), 62 kinase
inhibitors have been approved, among them 52 kinase
inhibitors are Tyrosine kinase inhibitors (TKI) (2). The intense
effort in this area has also led to the development of many TKIs
that were unsuccessful in clinical trials mainly due to insufficient
efficacy for humans. However, second opportunities exist for the
failed TKIs as a consequence of drug repositioning, which
focusses on discovering new applications of existing
therapeutic agents (3, 4). Because substances can interact with
more than one target protein (5), they have the potential of
having more than one pharmacological function. Furthermore,
owing to its relatively low cost and risk, and time-saving nature,
drug repositioning is an effective strategy in drug development.
So far, over 14 existing drugs have been successfully repositioned
and several promising candidates are in different stages of clinical
trials exploring their new uses (6).
Neurotrophin receptors tyrosine kinase (NTRK) genes encode
Tropomyosin-related kinases, which are receptors for different
neurotrophins [TRKA is for NGF, TRKB is for BDNF and NT4,
and TRKC is for Neurotrophin3 (NT3)] (7, 8). Chromosomal
rearrangement of NTRKs with upstream partner genes including
TPM3, ETV6 and LMNA leads to oncogenic TRK activation (8).
The NTRK gene fusions are found in various tumor patients across
histologies that include colorectal cancer, NSCLC, thyroid
carcinomas, and glioblastoma (9, 10). Although NTRK fusion
genes occur in less than 1% of all solid tumors, TRK inhibitors
display remarkable therapeutic responses (11). Therefore, several
TRKA/B/C inhibitors have been developed and subjected to clinical
trials (12–24). Among this group, LOXO101 (larotrectinib,
VITRAKVI®), a potent and selective TRKs inhibitor, and
entrectinib (Rozyltrek®) have been recently approved in the U.S.A
and Japan, respectively, for the treatment of patients who have a
NTRK gene fusion, regardless of the cancer type (25–27). The
unusual FDA approval for LOXO101 demonstrates the importance
of TRKA/B/C in terms of targeted anticancer therapy.
AZD4547, first developed as a potent fibroblast growth factor
receptor (FGFR) inhibitor, exhibits remarkable in vitro potencies
against FGFRs 1–3 (IC50 = 0.2 nM for FGFR1, 2.5 nM for FGFR2,
and 1.8 nM for FGFR3). In addition, it is highly selective against
FGFR1-3 in that AZD4547 inhibits only two other kinases
(Insulin-Like Growth Factor 1 Receptor (IGFR1) and Kinase
Insert Domain Receptor (KDR) at sub-mM IC50s (28). The
recent phase II clinical trials of AZD4547 for the patients with
FGFR genetic mutations are completed (NCT02465060) with
failure to meet the primary end point. Currently, phase 1b study
of multi-drugs including AZD4547 (NCT02546661) is undergoing
for the Muscle Invasive Bladder Cancer (29). Although a number
of clinical trials have shown that AZD4547 has acceptable safety,
tolerability and a moderate efficacy (30–33), they have not yet led
to FDA approval. These failures have stimulated efforts to seek
new applications of AZD4547. Unlike the diverse number of
studies that have focused on the anti-tumor properties ofFrontiers in Oncology | www.frontiersin.org 2AZD4547 against FGFRs-deregulated tumor cell lines (34), the
investigation described below was aimed at exploring new targets
by testing the anti-tumor effects of this substance that are not
related to FGFR mutations. The results of this study, in which we
assessed the anti-proliferative activity of AZD4547 on 64 cancer
cell lines having different mutational status, demonstrated that
AZD4547 potently suppresses proliferation of KM12(Luc), which
has the TPM3-NTRK1 fusion gene that drives colon cancer (35),
and Ba/F3 harboring TRKA/B. Moreover, AZD4547 has a
comparable in vivo efficacy in the KM12(Luc) tumor xenograft
model. Finally, the results of this study show for the first time that
AZD4547 directly inhibits TRKA/B/C activity as well as FGFRs.MATERIALS AND METHODS
Reagents
Inhibitors, including AZD4547 (MedChemExpress, HY-13330)
were purchased from the indicated companies. For use in the
apoptosis assay, Alexafluor488 conjugated annexin V (A13201)
and propidium iodide (P3560) were purchased from Thermo
Fisher Scientific. For use in cell cycle analysis, propidium iodide
in a RNase containing solution (#4087) was obtained from Cell
Signaling Technology. Primary antibodies including phospho-
TRKA/B, phospho-AKT (Ser473, #4058), phospho-ERK1/2
(Thr202/Tyr204, #4370), ERK1/2 (#4695), phosphor-PLC-
gamma (Tyr783, #2821) and PARP-1 (#9542) were purchased
from Cell Signaling Technology. b-actin (SC-47778), DUSP6 (SC-
377070) and phospho-MEK1/2 (Ser218/222, SC-81503) were
purchased from Santa Cruz Biotechnology. AKT (A18120) and
MEK (A4868) were obtained fromAbclonal. Secondary antibodies
were purchased from genDEPOT. In the colony formation assay,
colonies are stained with iodonitrotetrazolium chloride (Sigma
Aldrich, #I8377).
Cell Culture
KM12(Luc)waspurchased fromthe JCRBcell bank.KM12(Luc)was
used within 6 months after purchase and the DNA profiles were
confirmed using a short tandem repeat (STR) analysis by the Korean
Cell Line Bank. KM12(Luc) cells were maintained in DMEM
supplemented with 10% FBS and antibiotics. Parental Ba/F3 cells
were purchased from DSMZ and were grown in RPMI1640
supplemented with 10% FBS and antibiotics in the presence of IL3,
Transformed Ba/F3 cell lines were grown in the samemedia without
IL3. Cells used in this study were negative for mycoplasma
contamination. AN3-CA, HEC1A, U138, 8505C, MKN28,
MKN45, A172, A375, Capan-1 HeLa, HEP3B, MCF-7 and MIA-
paca-2 cells were maintained in DMEM (Welgene, Korea)
supplemented with 10% FBS and antibiotics (Welgene,
Korea). Otherwise, all cells were maintained in RPMI (Welgene,
Korea) supplemented with 10% FBS and antibiotics
(Welgene, Korea).
Cell Viability Test
To obtain the GI50 value of a substance, cell viability was
measured using MTT (G4000, Promega, USA) for KM12(Luc)November 2021 | Volume 11 | Article 757598
Cho et al. Repositioning AZD4547 to Pan-TRK Inhibitorcell and Cell titer glo (G7572, Promega, USA) for other cell lines.
For adherent cells, cells were seeded at 5,000 cells/well in a 96-
well plate and treated with a substance one day after cell seeding.
For suspension cells, 10,000 cells/well were seeded and the
substance was treated after 4 h stabilization of cells. The
substance was treated at 10 points of 1:3 serial dilution (0–100
µmol/L) for 72 h. For MTT assay, 15 µL dye solution was added
to each well and incubated 4 h at 37°C. 100 µL of solubilization
solution was added and followed 1 hr incubation. Absorbance at
570 nm of each well was recorded using EnVision microplate
reader (Perkin Elmer). For Cell titer glo assay, Cell titer glo
reagent was treated in each well and measured the luminescence
by EnVision microplate reader (Perkin Elmer). Viable cells in
each well were normalized by using 0.5% DMSO-treated wells
(100%). The inhibitor dose−response curve was fitted and GI50
values were calculated using Prism 7.0 software (GraphPad). All
assays were performed in duplicate and the standard deviation
(SD) was determined from two independent experiments.
Establishment of Ba/F3 Stable Cell Lines
(ETV6-NTRKs)
To establish Ba/F3 cells expressing ETV6 fused TRKA or TRKB
kinase domains, plasmids containing TEL-fused humanNTRK1/2
kinase domain were inserted by retrovirus infection. For
mutagenesis PCR, QuikChange II Site-Directed Mutagenesis Kit
(#200523, agilent) was used. The primers used for establishing
point mutation are as follows: TRKA G595R (g1783a) 5-
agtata tgcggcacagggacctcaaccgc-3 , 5-gcggt tgaggtccct
gtgccgcatatact-3; TRKA G667A (g2000c) 5-gactggtggtcaa
gattgctgattttggcatgagc-3, 5-gctcatgccaaaatcagcaatcttgaccaccagtc-3;
TRKA G667S (g1999a) 5-ggactggtggtcaagattagtgattttggcatgagc-3,




Cells treated under the indicated condition were briefly washed
with ice-cold DPBS. Thereafter, cell lysates were prepared by
using a buffer solution containing 50 mM Tris-HCl pH7.5, 1%
NP40, 1 mM EDTA, 150 mMNaCl, 5 mMNa3VO4, 2.5 mMNaF
and a protease inhibitor cocktail (Roche, #11873580001). The
same amount of lysate was separated by using SDS-PAGE gel
and transferred to the PVDF membrane. All primary antibodies
were uniformly prediluted in TBS containing 0.05% Tween 20 at
1:1000 (v/v) whereas actin and all secondary antibodies were
prediluted in TBS containing 0.05% Tween 20 at 1:5000.
RT-PCR
Total RNAs of each cell were extracted by using TRIzol reagent
(Invitrogen) and 2 µg of total RNA was used to create cDNA using
M-MLV reverse transcriptase (Promega). The same amount of
cDNA was amplified by using PCR Cell safe premix (Cat#) for 32
cycle. Amplified PCR products were confirmed by using
electrophoresis in 3% agarose gels and visualized by Eco-star dye
(Biofect #ES301-1000). The primer sequences used in this study are
as follows: CCDN1(156bp) (36) 5-cctctgtgccacagatg-3 (forward), 5-
gggtcacacttgatcactc-3 (reverse); E2F1 (37) 5-gccactgactctgccaccatag-Frontiers in Oncology | www.frontiersin.org 33 (forward), 5-ctgcccatccgggacaac-3 (reverse); DUSP6
(38) 5-gagtc tgacct tgaccgagaccccaa-3 ( forward) , 5-
ttcctccaacacgtccaagttggtggagtc-3 (reverse); ETV1 (39) 5-
taccccatggaccacagatt-3 (forward), 5-cactgggtcgtggtactcct-3
(reverse); FOSL1 (40) 5-tgaccacaccctccctaactc-3 (forward), 5-
ctgctgctactcttgcgatga-3 (reverse); gapdh (41) 5-ggtggtctcc
tctgacttcaaca-3 (forward), 5-gttgctgtagccaaattcgttgt-3 (reverse);
FGFR1 (41) 5- cgcccctgtacctggagatcatca-3(forward), 5- ttggtacca
ctcttcatctt-3; FGFR2 (41) 5- gcctggaagagaaaaggagattac-3 (forward),
5- actgtacaccttgcagtgga -3(reverse); ETV6 5-atgatccgccgcctctcc-3
(forward); NTRK1 5- tggtggctgtcaaggcactg -3 (forward), 5-
gatctcccagagcaccacgc-3 (reverse); NTRK2 5- cacgcaaggacttccaccgt
-3 (forward), 5- ccaaatcgcggtgcacgaag-3 (reverse).
Apoptosis and Cell Cycle Analysis
For apoptosis assays, cells treated with under the indicated
condition were briefly washed with ice-cold DPBS. Thereafter,
the trypsinized cells were stained with Alexafluor488 conjugated
annexin V and propidium iodide according to the
manufacturer’s instructions. Apoptotic cells were monitored by
using Accuri C6 (BD Biosciences, USA). For cell-cycle analysis,
cells treated under the indicated condition were washed with ice-
cold DPBS. Thereafter, the trypsinized cells were fixed in 70%
ethanol at −20°C overnight. The cells were centrifuged at 500 g
for 10 min followed by twice washing with ice-cold DPBS, and
then stained with propidium iodide/RNase solution for 30 min.
The DNA content of each cell was determined by using Accuri
C6 (BD Biosciences, USA).
Anchorage Independent Assay
On the 1.6% bottom agar, 10,000 cells in the complete media
containing 0.8% agar were plated in 6-well plates. Indicated
substances in complete media were added in the top agar and
media and substances were refreshed twice a week. After 2 weeks
incubation, colonies from each well were stained with
iodonitrotetrazolium chloride (Sigma-Aldrich) for 24 h. The
entire area of each well was photographed and the colonies
were counted by using ImageJ software.
Xenograft Model
All animal procedures were approved by the KIST Laboratory
Animal Facilities and Use Committee and carried out in
AAALAC-accredited facilities. KM12(Luc) cells (2.5 × 106
cells/0.1 mL) were subcutaneously implanted into the right
flank of 7-week-old female balb/c nude mice (Orient Bio Inc.)
When the tumor volume reached around 100 mm3, the tumor-
bearing mice were randomly separated into 4 cohorts (n = 4 per
cohort). The vehicle substances are follows: 5% NMP, 15%
solutol, 30% PEG400 and 50% 0.05M citric acid. Mice were
orally gavaged once daily for Vehicle, AZD4547 or twice per day
for LOXO195 for 14 d. Tumor volume and body weight were
measured once every 2 d. The formula used to calculate tumor
volumes is tumor volume = 1/2 (length × width2)
Statistical Analysis
All data were analyzed with Graphpad prism version 7.0.0 for
window, Graphpad software, San Diego, California USA.November 2021 | Volume 11 | Article 757598
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legend. Standard error of mean (S.E.M) or standard deviation
(s.d) are indicated in each figure legends.RESULTS
Anti-Proliferation Activity of AZD4547 on
KM12(luc) Through Inhibition of NTRK
To identify AZD4547 sensitive cell lines other than FGFR-mutant
driven cancer cells, GI50 values were determined for AZD4547
against 64 different cancer cell lines, including AN3-CA used as a
positive control (Figure 1A and Table S1). Out of the 64 cell lines
five including KM12(Luc), AN3-CA, RT-112, U-2-OS and MV4-
11 have GI50 values for AZD4547 that are <1 µM. Among this
group, RT-112 harboring high expression of FGFR3 is a previously
reported cell line in which AZD4547 is a sensitive inhibitor (100-
200 nM of GI50) (42). Also, inhibitory activity of AZD4547 against
DDR1 or FLT3 allows suppression of proliferation of U-2-OS and
MV4-11 (43). Therefore, our attention focused on the inhibitory
activity of AZD4547 against KM12(Luc) cell lines which have the
TPM3-NTRK1 fusion gene. To exclude the possibility that the
anti-proliferation activity of AZD4547 against KM12(Luc) is a
common characteristic of FGFR inhibitors, we determined if
BGJ398, a representative FGFR inhibitor, is also capable of
suppressing proliferation of KM12(Luc) cells (Figure 1B). The
results show that BGJ398 has no inhibitory activity againstFrontiers in Oncology | www.frontiersin.org 4proliferation of KM12(Luc) cell lines indicating that the
inhibitory effect on KM12(Luc) is a unique feature of AZD4547.
Next, the anti-proliferation activity of AZD4547 on KM12(Luc)
was compared with those of the representative TRK inhibitors
entrectinib, LOXO101 and LOXO195 (Figure 1C). The result
shows that AZD4547 has a comparable potency (GI50 = 49.74 nM)
to that of LOXO101 (GI50 = 31.64 nM). To determine whether
AZD4547 directly inhibits TRK kinase activity, we performed an
in vitro kinase assay against TRKs (Figure 1D). AZD4547 shows
great in vitro potencies with IC50 = 8.8 nM against TRKA, 7.6 nM
against TRKB and 1.0 nM against TRKC. Considering the
respective IC50s of AZD4547 against FGFR1, 2 and 3 are 0.2
nM, 2.5 nM and 1.8 nM, the observed inhibitory activity of
AZD4547 against TRKC is noteworthy. Compared to the IC50s
of LOXO101 and LOXO195, AZD4547 displays comparable
activity on TRKC to that of LOXO195 (IC50 = 0.68 nM against
TRKC) although both LOXO101 and LOXO195 exhibit higher
activities on TRKA and TRKB than AZD4547.To show that
AZD4547 inhibits phosphorylation of TRKs at the cellular level,
western blot analysis was conducted (Supplementary Figure 1A).
the results demonstrate that 1 µM AZD4547 completely
suppresses phosphorylation of TRKA/B while BGJ398 and
PD173074, other representative FGFR inhibitors, do not inhibit
phosphorylation of TRKA/B. This finding indicates that inhibition
of TRK by AZD4547 is not related to inhibition of FGFRs. Based
on these results, we conclude that AZD4547 inhibits a pan-TRK as
well as FGFRs.A
B C D
FIGURE 1 | AZD4547 is pan-TRK inhibitor. (A) Results of cancer cell screening of AZD4547 against 64 cancer cell lines. GI50 of AZD4547 against 64 cancer cell
lines are measured after 72 h incubation of serial diluted AZD4547. (B) Anti-proliferation activity of AZD4547 and BGJ398 on KM12(Luc). Cell viability of KM12(Luc)
after 72 h exposure to AZD4547 or BGJ398 were determined by using a cell titer glo assay. (C) GI50 values of TRK inhibitors and AZD4547 against KM12(Luc). GI50
values were determined by using an MTT assay after 72 h exposure to the indicated substances. All experiments are duplicate mode and each GI50 is an average of
two independent assays. (D) IC50 of AZD4547 against TRK isotypes. *Each of IC50 was obtained by using a radiometric biochemical kinase assay.November 2021 | Volume 11 | Article 757598
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To investigate the inhibitory activity of AZD4547 against
clinically relevant TRK mutants which have resistance to the
known TRK inhibitors (8, 44), we established Ba/F3 cell lines
harboring the ETV6-NTRKs fusion genes (NTRK1,
NTRK1G595R, NTRK1G667A, NTRK1G667C, NTRK1G667S
and NTRK2) (Supplementary Figure 2). The mutation status
of each established cell line was confirmed by sequencing of its
cDNA (Supplementary Figure 2). The anti-proliferation activity
of AZD4547 was then measured in each cell line (Figure 2A and
Table S2). As expected, AZD4547 significantly inhibits the
proliferation of Ba/F3: TRKA (GI50 = 66 nM) and Ba/F3:
TRKB (GI50 = 100 nM). However, AZD4547 has no inhibitory
activity against Ba/F3 harboring clinically relevant TRKs
mutants including TRKA G595R, TRKA G667S, TRKA G667C
and TRKA G667A. We next evaluated if AZD4547 is capable of
suppressing the phosphorylation of TRKA/B in Ba/F3 cell lines
(Figure 2B). Treatment with AZD4547 for 2 h leads to potent
dose-dependent inhibition of phosphorylation of TRKA/B and
PLC-gamma. Also, phosphorylation of TRKA/B is almost
completely abolished using 1 µM of AZD4547. These resultsFrontiers in Oncology | www.frontiersin.org 5indicate that the inhibitory activity of AZD4547 against TRKA/B
is well translated into a cellular context.
AZD4547 Impedes TRKs Signaling
Pathway in KM12(Luc)
Next, the capability of AZD4547 to block the TRK pathway in
KM12(Luc) (TPM3-NTRK1) was evaluated. For this purpose, we
analyzed the phosphorylation level of TRKA/B and its downstream
molecules by using western blotting (Figure 3A). Treatment of
AZD4547 for 2 h leads to inhibition of TRKA/B phosphorylation
in a dose-dependent manner and phosphorylation of TRKA/B is
completely abolished at 1 µM of AZD4547. Because the PLC-
gamma and Akt pathways are known to be regulated by the TRK
pathway (7), we also monitored the phosphorylation levels of the
PLC-gamma and Akt. In the presence of AZD4547,
phosphorylation of PLC-gamma and Akt decreases in an
AZD4547 dose-dependent manner. It is noteworthy that
inhibition of phosphorylation by AZD4547 is comparable to that
by LOXO195, which a promising next-generation TRK Inhibitor.
The effect of AZD4547 onMAPK signaling a downstream pathway
of TRK was also assessed. The results show that phosphorylation ofA
B
FIGURE 2 | Effects of AZD4547 on TRKA kinase mutants and TRKB. (A) Summary of GI50s of AZD4547 against Ba/F3: TRKA mutants or TRKB. Cell viability after
72 h exposure to the indicated inhibitors, determined by using a cell titer glo assay in duplicate mode. Data was plotted as mean GI50 ± SD of two independent
experiments. (B) AZD4547 inhibits phosphorylation of TRKA/B and PLC-gamma in Ba/F3 harboring TRKA and TRKB, respectively. The phosphorylation level of
TRKA/B and PLC-gamma were monitored after 2 h treatment with AZD44547 or LOXO195. Data are representative of three independent experiments.November 2021 | Volume 11 | Article 757598
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AZD4547 (Figure 3B). Moreover, protein expression of DUSP6,
one of the target genes of MAPK, is downregulated by AZD4547
treatment for 24 h (Figure 3C). Moreover, the consistent result of
DUSP6 expression was observed in RT-PCR assay (Figure 3D).
AZD4547 treatment for 24 h results in a decrease in mRNA levels
of MAPK target genes including ETV1 and DUSP6. Because
expression of E2F and CCND1 are also down-regulated by TRK
inhibitors (18), we monitored their mRNA levels (Figure 3C).
AZD4547 dose dependently impedes expression of E2F1 and
CCND1. Together, the observations show that AZD4547 not
only suppresses phosphorylation of TRK but also the
downstream pathway of TRK in KM12(Luc).
Anti-Tumor Activity of AZD4547 Against
KM12(Luc) (TPM3-NTRK1)
Several in vitro experiments were conducted to evaluate the anti-
tumor activity of AZD4547 in KM12(Luc) (TPM3-NTRK1).
First, we examined the effect of AZD4547 on the cell cycle of
KM12(Luc) (Figure 4A and Supplementary Figure 3A).
Significant SubG0/G1 arrest (P < 0.001) was observed to occur
in association with AZD4547 or LOXO195 treatment for 24 h.
This result is consistent with the finding (Figure 3C) that
AZD4547 suppresses CCND1 expression, which is associated
with the G1-S transition in the cell cycle (45). In addition, the
number of apoptotic cells also increases after treatment with 1
µM of AZD4547 for 48 h, which is comparable to the increase
brought about by LOXO195 (Figure 4B and Supplementary
Figure 3B). Furthermore, AZD4547 induces apoptosis of KM12
(Luc) in a time and dose dependent manner (Figure 4C andFrontiers in Oncology | www.frontiersin.org 6Supplementary Figure 3C). Upregulation of cleaved PARP1 by
AZD4547 is also observed in KM12(Luc) (Figure 4D). Next, we
determined the ability of AZD4547 to suppress tumorigenesis of
KM12(Luc) by assessing its ability to block anchorage
independent growth. The results of a soft agar assay in KM12
(Luc) cells (Figure 4E) showed that complete suppression of
colony formation and a reduction in size occurs after 14 d
treatment with AZD4547. In order to show that the anti-tumor
effect of AZD4547 against KM12(Luc) is caused by inhibition of
TRKs rather than FGFR, we monitored mRNA levels of FGFR1/2
and NTRK1/2 in KM12(Luc) (Supplementary Figure 1B). The
finding that FGFR1 is hardly expressed and NTRK1 mRNA
expression is high provides clear evidence for the anti-tumor
effect of AZD4547 in KM12(Luc) (TPM3-NTRK1).
In Vivo Efficacy of AZD4547 in the KM12
(Luc) Xenograft Model
The results of in vitro studies that show that AZD4547 has
comparable activities to those of LOXO195 led us to examine the
in vivo efficacy of AZD4547 in the KM12(Luc) xenograft model.
The balb/c nude mice bearing KM12(Luc) xenograft tumor were
randomly grouped in 4 cohorts (vehicle, AZD4547 20 mpk,
AZD4547 40 mpk or LOXO195 20 mpk, n = 4) and each group
was orally administrated (q.d for vehicle or AZD4547, b.i.d for
LOXO195). The results show that tumor growth in the AZD4547
treated group is remarkably delayed compared to that of the
vehicle treated group (Figures 5A, B). During the time interval
in which the tumor size of the vehicle treated group reached 1500
mm3, the tumor size of the group administered with 20 mpk of
AZD4547 reached 600 mm3 and that of the 40 mpk AZD4547A B
C
D
FIGURE 3 | AZD4547 suppresses phosphorylation of TRKA/B and its downstream substances. (A) AZD4547 inhibits phosphorylation of TRKA/B, PLC-gamma and
AKT in KM12(Luc). The phosphorylation level of TRKA/B, PLC-gamma and AKT were monitored after 2 h treatment with AZD44547 or LOXO195. Data are
representative of two independent experiments. (B) AZD4547 decreases MAPK signaling in KM12(Luc). AZD4547 or LOXO195 treated for 2 h against KM12(Luc).
Level of phospho- MEK1/2 and ERK1/2 were evaluated by western blot. Data are representative of two independent experiments. (C) AZD4547 treatment reduces
the DUSP expression level in KM12(Luc). After 24 h treatment with the indicated substances, the cell lysates were subjected to western blot with DUSP6 antibody.
Data are representative of two independent experiments. (D) AZD4547 blocks the MAPK and E2F pathways. After treatment of AZD4547 or LOXO195 for 24 h, total
RNA was extracted, and cDNA was synthesized. Each cDNA was amplified by using the indicated primer for comparison of mRNA levels. (average ± SEM, n=3,
twoway Anova, * < 0.05, ** < 0.005, *** < 0.001, ****p < 0.0001).November 2021 | Volume 11 | Article 757598
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tumor weight of vehicle treated group was around 1.2 g, that of
the 20 mpk AZD4547 treated group was 0.78 g and that of the 40
mpk AZD4547 treated group was 0.69 g. Reduction in body
weight did not occur in all groups (Figure 5C). To confirm that
the reduced tumor sizes are caused by TRK inhibition, we
performed immunohistochemical staining of tissues of tumors
from the vehicle and 40 mpk AZD4547 treated group
(Figure 5D). In contrast to that in the vehicle group, decreased
phosphorylation of TRKA took place in the 40 mpk AZD4547
treated group, which indicates that AZD4547 effectively inhibits
phosphorylation of TRKA in vivo.DISCUSSION
Drug repurposing is an effective approach to discover a new
indication for an existing drug. Compared with the traditional
drug development process, comprised of five stages including
discovery, preclinical evaluation, safety review, clinical studies, and
FDA review and post-market safety monitoring, the drug
repurposing approach requires only four stages involving
compound identification, acquisition and development, and FDA
post-market safetymonitoring. Thus, the drug repurposing protocol
leads to time and money savings (4). A number of existing drugs
developed employing this strategy are under clinical trials or have
been remarketed for different indications (46).Frontiers in Oncology | www.frontiersin.org 7As background for the drug repurposing study described
here, we made the novel observation that AZD4547 is active
against FGFR2-mutated endometrial cancers (43). AZD4547 is a
selective kinase inhibitor targeting FGFR1/2/3 (28). The high in
vitro potency of AZD4547 against cancer cells expressing FGFR
mutations, including non-small cell lung cancer, breast cancer
and gastric cancer cell lines, stimulated several clinical studies on
patients who have a FGFR mutation. However, this substance
has not yet received FDA approval (34). It is of note that studies
of AZD4547 carried out to date focused only on tumor cell lines
derived from FGFR mutants. This realization suggests the need
to initiate a drug repurposing effort to probe the potential effects
of AZD4547 on sensitive cancer cell lines other than just FGFR-
mutant related cancers.
To investigate the cancer cell growth inhibitory activity of
AZD4547, we examined its anti-proliferative activity against 64
cancer cell lines. To our surprise, the results of this exploratory
investigation revealed that AZD4547 strongly inhibits proliferation
of KM12(Luc) harboring the TPM3-TRKA rearrangement, which is
known to be tumor sensitive for TRKA kinase inhibition (35).
Considering the fact that the FGFR inhibitor BGJ-398 has no effect
on proliferation of KM12(Luc), we assumed that AZD4547 directly
inhibits TRKA kinase activity. Using an in vitro kinase assay, we
unequivocally demonstrated for the first time that AZD4547
exhibits remarkable in vitro potencies against TRKA/B/C (IC50 =
8.8 nM for TRKA, 7.6 nM for TRKB, and 1.0 nM for TRKC). In




FIGURE 4 | Anti-tumor effect of AZD4547 on KM12(Luc) (TPM3-NTRK1). (A) AZD4547 induces SubG1/G1 arrest. KM12(Luc) cells were treated with the indicated
substances for 24 h. After fixation with 70% ethanol, cells were stained with PI containing RNase. Then, DNA contents of cells were analyzed by using flow
cytometry. (average ± SD, n=3, two-way Anova; Dunnett’s multiple comparisons test; * < 0.05 *** < 0.001, ****p < 0.0001) (B) Apoptosis is induced by AZD4547
and LOXO195. (average ± SD, n=3 one-way Anova; ****p < 0.0001) (C) Time and dose dependent increases of apoptotic cells caused by AZD4547 treatment.
(average ± SD, n=3 one-way Anova; ** <0.01, *** < 0.001 ****p < 0.0001) (D) Apoptotic marker, cleaved PAR-1 is up-regulated by AZD4547. (E) AZD4547
suppresses anchorage independent growth of KM12(Luc). (average ± SD, n=5 one-way Anova; *** < 0.001, ****p < 0.0001).November 2021 | Volume 11 | Article 757598
Cho et al. Repositioning AZD4547 to Pan-TRK InhibitorTRKAs, it is known that three hydrogen bonds between the
pyrazole amide of AZD4547 and the hinge region (E562 and
A564) of FGFR1 are critical for binding (47). TRKA/B/C also
have an EYM motif which corresponds to E562-Y-A564 of
FGFR1/2/3 (3), suggesting that AZD4547 bind to the EYM motif
of TRKA/B/C.
NTRK genes encoding the neurotrophin receptors TRKA,
TRKB and TRKC are oncogenic drivers of various tumor types.
Intra/inter-chromosomal rearrangements of the NTRK gene
with partner genes including TPM3 and ETV6 lead to
constitutive activation of TRK kinases. Even though the NTRK
fusion gene (<1%) is infrequently present in solid tumors, first
generation TRK inhibitors like LOXO101 display remarkable
response rates (>75%) in patients in which this fusion is found
(8). The high levels of response led to FDA approval of
LOXO101 for the treatment of NTRK fusion positive tumors,
regardless of tumor histology.
Acquired resistance to first generation TRK inhibitors has
been observed and attributed to amino acid substitution at the
solvent front region, activation loop or gate keeper residue of
TRKA. Next generation TRK inhibitors such as LOXO195 and
TRX-005, which inhibit many of the aforementioned TRK
mutants, are currently being evaluated in clinical studies for
safety and efficacy (8). To determine if AZD4547 is capable of
inhibiting those mutants, we utilized ETV6-TRKA/B
transformed Ba/F3 cell lines. Unfortunately, the results show
that AZD4547 has little effect on growth of Ba/F3 cells containingFrontiers in Oncology | www.frontiersin.org 8the clinically relevant TRKA mutants including G595R, G667A,
G667S and G667C. Type II-NTRK inhibitors (e.g. altiratinib,
caboztinib, and foretinib) are more potent than type I inhibitors
against entractibnin and larotrectinib-resistant TRKA mutations
(G667C, V573M and F589L) (48). Thus, it might be possible to
increase potency against drug resistant mutants by modifying
AZD4547 (a type I inhibitor) to make it structurally more like
type II kinase inhibitors.
The anti-tumor activity of AZD4547 was also evaluated in
KM12(Luc) colon cancer cells harboring the TPM3-NTRK1
fusion gene. AZD4547 dose dependently blocks phosphorylation
of TRKA/B and its downstream molecules including PLC-gamma
and AKT. Like that with other TRK inhibitors, treatment with
AZD4547 for 24 h results in down regulation of DUSP6, ETV1, E2F
and CCND1. Because CCND1 is related with G1-S transition in the
cell cycle, we performed cell cycle analysis after 24 h AZD4547
treatment. The results show that AZD4547 leads to Sub G1/G1
arrest of KM12(Luc) cells in a dose dependent manner. In addition,
AZD4547 induces apoptosis and blocks tumorigenesis in the soft
agar assay. A comparison of mRNA levels by using RT-PCR shows
that expression of FGFR1/2 in KM12(Luc) cells is very low.
Phosphorylation of FGFR1/2 in KM12(Luc) is undetectable by
using western blot (data not shown), indicating that the anti-
tumor effect of AZD4547 is a consequence of inhibition of
TRKA/B rather than FGFR. An in vivo efficacy test in the KM12
(Luc) xenograft model demonstrates that AZD4547 blocks tumor
growth by inhibiting phosphorylation of TRKA. The anti-tumorA B
C
D
FIGURE 5 | In vivo efficacy of AZD4547 in the KM12(Luc) xenograft model. (A) AZD4547 treatment significantly delayed tumor growth. KM12(Luc) implanted mice
were administered by oral gavage (p.o, q.d for vehicle and AZD4547, b.i.d for LOXO195) with the indicated dosage (n = 4, Allow indicates the administration starting
day. Tukey’s multiple comparisons test, **** < 0.0001). Tumor volume (mm3) was measured once every 2 d. Data was plotted as mean ± SD (n=4) (B) Tumor weight
was measured at the end of the experiment. (Dunnett’s multiple comparisons test, ** < 0.005, *** < 0.001, **** < 0.0001) (C) Body weight was monitored during the
experiment. (D) Immunohistochemical staining of paraffin-embedded tumor sections using phospho-TRKA antibody. IHC images were obtained at 200X
magnification. The data represent tumor tissue from each group.November 2021 | Volume 11 | Article 757598
Cho et al. Repositioning AZD4547 to Pan-TRK Inhibitoractivities of AZD4547 in this study are overly lower than those of
LOXO195, which is a frontrunner inhibitor against TRKs.CONCLUSION
In summary, the above effort focused on finding therapeutic
applications of AZD4547 other than those associated with FGFR
inhibition. A screen of 64 cancer cell lines showed that AZD4547
significantly suppresses proliferation of KM12(Luc) cells via
inhibition of TRKA kinase activity. Moreover, we found that
AZD4547 has a potency (GI50 = 49.74 nM) that is comparable to
that of LOXO101 (GI50= 31.64nM), an approvedNTRK inhibitor. It
is worth noting that LOXO101 is the first approved drug to treat any
cancers harboring certain mutations. We also demonstrated that
AZD4547 significantly blocks proliferation of Ba/F3 cells
transformed with TRKA (66 nM of GI50) and TRKB (100 nM of
GI50). However, AZD4547 has no anti-proliferative activity against
Ba/F3 cells harboring clinically relevant TRK mutants. In addition,
AZD4547 not only suppresses phosphorylation of TRK, it also
perturbs the downstream pathway of TRK in KM12(Luc) cells.
Furthermore, we demonstrated that AZD4547 exhibits an anti-
tumor effect on KM12(Luc) by perturbing the TRKA pathway
including phosphorylation of PLC-gamma and expression of
DUSP6 and ETV1. Apoptotic cells are also increased by AZD4547
treatmentwhich in amanner that is comparable to that of LOXO195,
a promising next-generation NTRK inhibitor. AZD4547 induces
complete suppression of colony formation and reduces tumor size in
a soft agar assay. Furthermore,AZD4547 induces apoptosis of KM12
(Luc) in a time and dose dependent manner (Figure 4C and
Supplementary Figure 3C). Finally, AZD4547 potently delays
tumor growth in a KM12(Luc) xenograft model. The combined
results of the investigation lead to the unprecedented suggestion that
AZD4547exhibits therapeutic activity againstNTRKmutant derived
cancer cells by inhibiting TRKA signaling.Frontiers in Oncology | www.frontiersin.org 9DATA AVAILABILITY STATEMENT
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